NPS Pharmaceuticals' Gattex helps patients with short bowel syndrome who are off a time-consuming IV nutrition program, FDA staff said. Advisers might rely on this report when they vote Tuesday on whether to endorse approval. The FDA is set to make a final decision by Dec. 30.